Background And Objective: The aim of this study was to evaluate the efficiency of proton beam irradiation in pancreatic cancer cell line MIA PaCa-2 and its role in the cell cycle, apoptosis, and formation of histone γH2AX in different reparation times (72-h follow-up).
Material And Methods: The MIA PaCa-2 pancreatic carcinoma cell line was irradiated with 1.6-Gy proton beam. After irradiation, cell viability was measured colorimetrically, and the cell cycle, apoptosis, and γH2AX expression were evaluated on a FACScan cytometer.
Results: Low-dose proton beam irradiation had an effect on the MIA PaCa-2 tumor cell line already 1h after exposure, but maximal lethality was reached after 72h postirradiation with a cell viability rate of 24%. The cell cycle went into partial G1/0 arrest, and was released after 72h. The expression of γH2AX was strong and its levels were significantly elevated as late as 48h post radiation. The apoptosis levels increased with post radiation incubation time to reach 79% after 72h.
Conclusions: Our data demonstrate that low-doses proton beam irradiation had an effect on MIA PaCa-2 pancreatic carcinoma cell line. Full extent of irradiation had an impact only 24h postirradiation, triggering DNA arrested cell cycle in G1/0 phase. Formed DNA DSBs were found to be repaired via the NHEJ pathway mechanism within 72h. Unsuccessful repaired DSBs induced apoptotic cell death. After 72h reparation processes were completed, and cell cycle was released from arrest in G1/0 phase.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.medici.2015.10.002 | DOI Listing |
BMC Cancer
December 2024
ISTCT UMR 6030-CNRS, Université de Caen-Normandie, Caen, 14000, France.
Background: Proton therapy (PRT) is an innovative radiotherapeutic modality for the treatment of cancer with unique ballistic properties. The depth-dose distribution of a proton beam reduces exposure of healthy tissues to radiations, compared with photon-therapy (XRT). To date, only few indications for proton-therapy, like pediatric cancers, chordomas, or intra-ocular neoplasms, are reimbursed by Health systems.
View Article and Find Full Text PDFJ Radiat Res
December 2024
Section of Radiation Safety and Quality Assurance, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
We assessed the effect of beam size on plan robustness for intensity-modulated proton therapy (IMPT) of head and neck cancer (HNC) and compared the plan quality including robustness with that of intensity-modulated radiation therapy (IMRT). IMPT plans were generated for six HNC patients using six beam sizes (air-sigma 3-17 mm at isocenter for a 70-230 MeV) and two optimization methods for planning target volume-based non-robust optimization (NRO) and clinical target volume (CTV)-based robust optimization (RO). Worst-case dosimetric parameters and plan robustness for CTV and organs-at-risk (OARs) were assessed under different scenarios, assuming a ± 1-5 mm setup error and a ± 3% range error.
View Article and Find Full Text PDFRev Sci Instrum
December 2024
Plasmaphysics Department, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstrasse 1, 64291 Darmstadt, Germany.
A new high energy proton radiography facility PRIOR-II (Proton Microscope for FAIR) has been designed, constructed, and successfully commissioned at the GSI Helmholtzzentrum für Schwerionenforschung (Darmstadt, Germany) pushing the technical boundaries of charged particle radiography with normal conducting magnets to the limits. The setup is foreseen to become a new and powerful user facility for carrying out fundamental science experiments in the fields of plasma and shock wave physics, material science, and medical physics. It will help address several unsolved scientific challenges, which require high-speed and precise non-invasive diagnostic methods capable of probing matter with up to 100 g/cm2 areal density.
View Article and Find Full Text PDFAppl Radiat Isot
December 2024
Institute of Nuclear Techniques of Budapest University of Technology and Economics, Műegyetem Rkp 9, 1111, Budapest, Hungary.
This study presents a compact accelerator-driven neutron source design with a thermal neutron port and an epithermal neutron port for Boron Neutron Capture Therapy (BNCT), based on 10 mA 2.5 MeV protons bombarding on a 100 μm thick disc-shaped Li target with a diameter of 10 cm. The moderator consists of 2 parts, the epithermal neutron moderator and the thermal neutron moderator.
View Article and Find Full Text PDFMed Phys
December 2024
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Background: Rapid planning is of tremendous value in proton pencil beam scanning (PBS) therapy in overcoming range uncertainty. However, the dose calculation of the dose influence matrix (D) in robust PBS plan optimization is time-consuming and requires substantial acceleration to enhance efficiency.
Purpose: To accelerate the D calculations in PBS therapy, we developed an AI-D engine integrated into our in-house treatment planning system (TPS).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!